After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit against 5 companies over the development of Brenzys, an etanercept biosimilar, in Australia.
Pfizer and its subsidiary Hospira were previously involved in a patent dispute over the development and marketing of its biosimilars referencing Neupogen (filgrastim) and Neulasta (pegfilgrastim), both of which were developed by Amgen and are used to treat patients undergoing chemotherapy who are at risk of developing febrile neutropenia.
According to reports from Bloomberg Law, Amgen settled with Pfizer in September 2021 for its filgrastim biosimilar and in March 2022 for its pegfilgrastim biosimilar. However, Pfizer seems to be taking a page out of Amgen’s handbook by filing a patent lawsuit against Samsung Bioepis, Merck, Sharp & Dohme, Organon, and Arrow to stop the marketing of Brenzys, which is a biosimilar referencing Enbrel (etanercept), in Australia.
In the court documents, Pfizer alleged that the respondents infringed Australian Patent No. 2005280034, a patent that covers cell culture methods. Brenzys; also known as SB4, Eticovo, and Benepali depending on the country where the drug is being marketed; was approved for use by Australia’s Therapeutic Good Administration in 2016.
Although reference product manufacturers frequently sue biosimilar manufacturers over patent infringement, often resulting in pay-for-delay agreements, in which the biosimilar manufacturer is paid by the reference biologic manufacturer to delay entry of the biosimilar to the market, Pfizer is seeking damages from the sales of the biosimilar in Australia and for the barring of future sales of the drug until Pfizer’s patent expires.
Currently, Pfizer shares marketing rights with Amgen over reference etanercept. Amgen is notorious for suing biosimilar manufacturers to delay etanercept competition in the United States, where etanercept biosimilars are barred from entering the market until 2029. There are currently 2 FDA-approved etanercept biosimilars, including Eticovo (etanercept-ykro).
In the European Union, Brenzys is marketed as Benepali and was granted marketing authorization in January 2016. There are a total of 3 etanercept biosimilars approved in the European Union.
In 2016, Brenzys was approved in Canada for the treatment of moderate-to-severe rheumatoid arthritis in adults and ankylosing spondylitis. In September 2020, it received expanded indications to include plaque psoriasis, psoriatic arthritis, and juvenile idiopathic arthritis. There are 2 etanercept biosimilars approved in Canada. Brenzys was also approved for marketing in Brazil in September 2019.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.